{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:26:30Z","timestamp":1767191190243,"version":"3.48.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":58,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rceng.2025.502370","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T14:42:27Z","timestamp":1759675347000},"page":"502370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of angiogenic and inflammatory biomarkers in patients with hereditary hemorrhagic telangiectasia during treatment with bevacizumab: study protocol"],"prefix":"10.1016","volume":"225","author":[{"given":"B.","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Figueras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Torres-Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Moreno-Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Trull\u00e9n-Malaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Vi\u00f1als","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-804X","authenticated-orcid":false,"given":"A.","family":"Riera-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2025.502370_bib0005","unstructured":"The portal for rare diseases and orphan drugs (https:\/\/www.orpha.net\/, Accessed 22 July 2024)."},{"key":"10.1016\/j.rceng.2025.502370_bib0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.blre.2010.07.001","article-title":"Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment","volume":"24","author":"Shovlin","year":"2010","journal-title":"Blood Rev."},{"key":"10.1016\/j.rceng.2025.502370_bib0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.medcli.2018.09.015","article-title":"Medical management of hemorrhagic hereditary telangiectasia in adult patients","volume":"152","author":"Riera-Mestre","year":"2019","journal-title":"Med Cl\u00ednica."},{"key":"10.1016\/j.rceng.2025.502370_bib0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.rceng.2025.502370_bib0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am J Med Genet."},{"key":"10.1016\/j.rceng.2025.502370_bib0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13023-020-01422-8","article-title":"Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry","volume":"15","author":"S\u00e1nchez-Mart\u00ednez","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rceng.2025.502370_bib0035","first-page":"1","article-title":"Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era","volume":"5","author":"McDonald","year":"2015","journal-title":"Front Genet."},{"key":"10.1016\/j.rceng.2025.502370_bib0040","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/VB-21-0019","article-title":"Rethinking growth factors: the case of BMP9 during vessel maturation","volume":"4","author":"Medina-Jover","year":"2022","journal-title":"Vasc Biol."},{"issue":"23","key":"10.1016\/j.rceng.2025.502370_bib0045","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.3390\/ijms21239247","article-title":"Endoglin: an \u2018Accessory\u2019 receptor regulating blood cell development and inflammation","volume":"21","author":"Meurer","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"4","key":"10.1016\/j.rceng.2025.502370_bib0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176379","article-title":"Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances","volume":"134","author":"Al Tabosh","year":"2024","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rceng.2025.502370_bib0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0028-1085093","article-title":"Hepatic vascular malformations in hereditary hemorrhagic telangiectasia","volume":"28","author":"Khalid","year":"2008","journal-title":"Semin Liver Dis."},{"issue":"2","key":"10.1016\/j.rceng.2025.502370_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228486","article-title":"Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia","volume":"15","author":"V\u00e1zquez","year":"2020","journal-title":"PLoS One."},{"key":"10.1016\/j.rceng.2025.502370_bib0065","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1002\/ajh.24878","article-title":"Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia","volume":"92","author":"Chavan","year":"2017","journal-title":"Am J Hematol."},{"key":"10.1016\/j.rceng.2025.502370_bib0070","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA."},{"key":"10.1016\/j.rceng.2025.502370_bib0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.rce.2018.07.002","article-title":"Computerized registry of patients with hemorrhagic hereditary telangiectasia (RiHHTa registry) in Spain: objectives, methods, and preliminary results","volume":"218","author":"Riera-Mestre","year":"2018","journal-title":"Rev Clin Esp (Barc)."},{"key":"10.1016\/j.rceng.2025.502370_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/gim.2013.62","article-title":"Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes","volume":"16","author":"Canzonieri","year":"2014","journal-title":"Genet Med."},{"key":"10.1016\/j.rceng.2025.502370_bib0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/jcm9010082","article-title":"Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia: risk factors and endoscopic findings","volume":"9","author":"Mora-Luj\u00e1n","year":"2019","journal-title":"J Clin Med."},{"key":"10.1016\/j.rceng.2025.502370_bib0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1572-0241.2003.07185.x","article-title":"Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia","volume":"98","author":"Longacre","year":"2003","journal-title":"Am J Gastroenterol."},{"issue":"10","key":"10.1016\/j.rceng.2025.502370_bib0095","article-title":"Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"12","author":"Torres-Iglesias","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.rceng.2025.502370_bib0100","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica."},{"key":"10.1016\/j.rceng.2025.502370_bib0105","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","article-title":"Biomarkers of cardiovascular disease: molecular basis and practical considerations","volume":"113","author":"Vasan","year":"2006","journal-title":"Circulation."},{"key":"10.1016\/j.rceng.2025.502370_bib0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejim.2021.09.003","article-title":"Translational medicine in hereditary hemorrhagic telangiectasia","author":"Riera-Mestre","year":"2022","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.rceng.2025.502370_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejim.2023.05.020","article-title":"Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases","volume":"115","author":"Villanueva","year":"2023","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.rceng.2025.502370_bib0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejim.2021.03.039","article-title":"Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia","volume":"88","author":"Iriarte","year":"2021","journal-title":"Eur J Intern Med."},{"issue":"1","key":"10.1016\/j.rceng.2025.502370_bib0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13023-019-1281-4","article-title":"Future treatments for hereditary hemorrhagic telangiectasia","volume":"15","author":"Robert","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rceng.2025.502370_bib0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol."},{"key":"10.1016\/j.rceng.2025.502370_bib0135","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1002\/lary.27548","article-title":"Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis","volume":"129","author":"Steineger","year":"2019","journal-title":"Laryngoscope."},{"issue":"1","key":"10.1016\/j.rceng.2025.502370_bib0140","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13023-021-02009-7","article-title":"Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations","volume":"16","author":"Wetzel-Strong","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rceng.2025.502370_bib0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan","year":"2011","journal-title":"J Med Genet."},{"key":"10.1016\/j.rceng.2025.502370_bib0150","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope."},{"issue":"1","key":"10.1016\/j.rceng.2025.502370_bib0155","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13023-024-03493-3","article-title":"Minimal encephalopathy in hereditary hemorrhagic telangiectasia patients with portosystemic vascular malformations","volume":"19","author":"Villanueva","year":"2024","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rceng.2025.502370_bib0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejim.2024.12.006","article-title":"Long-term follow-up of hereditary hemorrhagic telangiectasia patients without significant pulmonary right-to-left shunt at screening","volume":"132","author":"Villanueva","year":"2024","journal-title":"Eur J Intern Med."},{"issue":"19","key":"10.1016\/j.rceng.2025.502370_bib0165","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11195624","article-title":"Perioperative complications and long-term follow-up of liver transplantation in hemorrhagic hereditary telangiectasia: report of three cases and systematic review","volume":"11","author":"Riera-Mestre","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.rceng.2025.502370_bib0170","article-title":"Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"10","author":"Torres-Iglesias","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.rceng.2025.502370_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpnec.2021.100052","article-title":"How to deal with non-detectable and outlying values in biomarker research: best practices and recommendations for univariate imputation approaches","volume":"7","author":"Herbers","year":"2021","journal-title":"Compr Psychoneuroendocrinol."},{"key":"10.1016\/j.rceng.2025.502370_bib0180","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick","year":"2005","journal-title":"Haematologica."},{"key":"10.1016\/j.rceng.2025.502370_bib0185","first-page":"575","article-title":"Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF?","volume":"22","author":"Sadick","year":"2008","journal-title":"Int J Mol Med."},{"key":"10.1016\/j.rceng.2025.502370_bib0190","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cca.2009.12.023","article-title":"Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT)","volume":"411","author":"Ojeda-Fernandez","year":"2010","journal-title":"Clin Chim Acta."}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425001055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425001055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:23:57Z","timestamp":1767191037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887425001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2254887425001055"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2025.502370","relation":{},"ISSN":["2254-8874"],"issn-type":[{"type":"print","value":"2254-8874"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of angiogenic and inflammatory biomarkers in patients with hereditary hemorrhagic telangiectasia during treatment with bevacizumab: study protocol","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2025.502370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2025.502370","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502370"}}